Impact of Oral Antidiabetics Agents in the Prevention of COPD Exacerbations
Arch Bronconeumol. 2023 Jul;59(7):412-413.
doi: 10.1016/j.arbres.2022.12.004.
Epub 2022 Dec 23.
[Article in
English,
Spanish]
Affiliations
- 1 Pneumology and Thoracic Surgery Service, Unit for Patients with Highly Complex COPD, University Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain; University Institute of Tropical Disease and Public Health of the Canary Islands, University of La Laguna, Santa Cruz de Tenerife, Spain. Electronic address: juanmarcofigueira@gmail.com.
- 2 Pneumology Service, University Hospital Lucus Augusti, Lugo, Spain.
No abstract available
MeSH terms
-
Anti-Bacterial Agents / therapeutic use
-
Bronchodilator Agents / therapeutic use
-
Disease Progression
-
Humans
-
Pulmonary Disease, Chronic Obstructive* / complications
-
Pulmonary Disease, Chronic Obstructive* / drug therapy
-
Pulmonary Disease, Chronic Obstructive* / prevention & control
Substances
-
Bronchodilator Agents
-
Anti-Bacterial Agents